<DOC>
	<DOCNO>NCT02973750</DOCNO>
	<brief_summary>While significant progress make treatment prognosis ovarian cancer , progress mostly show benefit young woman . This study aim understand two thing : How body composition ( amount muscle water versus fat body ) affect dose side effect chemotherapy ; biological reason bad prognosis age . To get good view effect , investigator ask help young old woman project .</brief_summary>
	<brief_title>Determinants Age-Related Treatment Effectiveness Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Peritoneal Diseases</mesh_term>
	<mesh_term>Fallopian Tube Diseases</mesh_term>
	<criteria>Participants must one following : ) Histological cytological diagnosis highgrade serous ovarian , fallopian , peritoneal cancer , stage III IV ; b ) In opinion investigator , highly suspicious stage III IV ovarian , fallopian , peritoneal cancer ( histologically confirm nonserous ovarian , fallopian , peritoneal cancer consider screening failure ) . At least one biopsiable lesion CT/US laparoscopy . Have receive previous treatment ovarian cancer . Life expectancy great 6 month . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 ( Karnofsky &gt; 60 % ) . Must adequate organ marrow function . Deemed eligible neoadjuvant chemotherapy carboplatin paclitaxel surgery oncologist . Women childbearing potential must agree use adequate contraception prior study entry duration study participation . Ability understand willingness sign write informed consent document . Active second malignancy within last 2 year ( except nonmelanoma skin cancer situ carcinoma . Prior treatment ovarian cancer . Potential participant know brain metastasis exclude clinical trial . History allergic reaction attribute compound similar chemical biologic composition carboplatin paclitaxel . Known allergy carboplatin , paclitaxel , cremophor . Uncontrolled concomitant illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Women pregnant . Breastfeeding discontinue mother treated carboplatin paclitaxel . These potential risk may also apply agent use study . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction carboplatin paclitaxel agent administer study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>high-grade serous cancer</keyword>
	<keyword>stage III cancer</keyword>
	<keyword>stage IV cancer</keyword>
</DOC>